◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › T › TGTX

TG Therapeutics Inc (TGTX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

TG Therapeutics Inc (TGTX) operates in the BIOTECHNOLOGY industry and is headquartered in Morrisville, United States with about 399 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, TGTX reported $616M in revenue and $447M in net income.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Interactive charts & full statements → Open the TGTX valuation workbench →

TGTX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$800M	$616M	$329M	$234M	$3M	$7M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—
Gross Profit	$658M	$516M	$291M	$220M	$3M	$6M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—
Gross Margin %	82.2%	83.7%	88.3%	94.0%	90.5%	88.2%	100.0%	100.0%	42.1%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	—	—	—	—	—	—
Operating Income (EBIT)	$136M	$123M	$42M	$21M	($218M)	($345M)	($274M)	($169M)	($174M)	($119M)	($79M)	($63M)	($56M)	($23M)	($27M)	($1M)	($2M)	($2M)	($4M)	($12M)	($10M)
Operating Margin %	17.0%	20.0%	12.7%	8.8%	-7839.0%	-5154.3%	-179996.0%	-111220.4%	-114736.8%	-77904.6%	-51823.5%	-41461.9%	-36567.0%	-15071.4%	-141196.5%	—	—	—	—	—	—
Net Income	$442M	$447M	$23M	$13M	($224M)	($348M)	($279M)	($173M)	($173M)	($118M)	($78M)	($63M)	($56M)	($20M)	($18M)	($1M)	$1M	($3M)	($4M)	($12M)	($10M)
Net Margin %	55.2%	72.6%	7.1%	5.4%	-8036.3%	-5204.1%	-183803.3%	-113730.9%	-114132.9%	-77749.9%	-51353.4%	-41310.0%	-36606.5%	-13438.8%	-94879.9%	—	—	—	—	—	—
EBITDA	—	$134M	$50M	$26M	($213M)	($342M)	($273M)	($167M)	($173M)	($119M)	($79M)	($63M)	($56M)	($20M)	($25M)	($1M)	$2M	($2M)	($4M)	($12M)	($10M)
Earnings Per Share (EPS)	$2.74	$2.77	$0.15	$0.09	$-1.65	$-2.63	$-2.42	$-1.96	$-2.30	$-1.91	$-1.60	$-1.38	$-1.64	$-0.81	$-1.38	$-0.44	$15.68	$-111.24	$-170.00	$-497.55	$-453.62
Shares Outstanding (M)	—	161M	160M	149M	135M	132M	115M	88M	75M	62M	49M	46M	34M	25M	—	2M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TGTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$240M	$205M	$193M	$162M	$141M	$121M	$108M	$84M	$73M
Gross Profit	$199M	$171M	$154M	$134M	$122M	$105M	$93M	$75M	$65M
Gross Margin %	82.9%	83.7%	80.2%	82.6%	86.6%	87.1%	85.8%	88.9%	88.7%
Operating Income (EBIT)	$22M	$35M	$50M	$29M	$35M	$9M	$30M	$12M	$9M
Operating Margin %	9.2%	17.0%	26.2%	18.2%	24.7%	7.1%	27.7%	14.8%	12.0%
Net Income	$8M	$20M	$23M	$391M	$28M	$5M	$23M	$4M	$7M
Net Margin %	3.3%	9.7%	12.0%	241.7%	20.0%	4.2%	21.6%	4.6%	9.4%
EBITDA	—	$28M	$52M	$33M	$38M	$12M	$33M	$15M	$11M
Earnings Per Share (EPS)	$0.05	$0.12	$0.14	$2.43	$0.17	$0.03	$0.15	$0.02	$0.04
Shares Outstanding (M)	—	160M	159M	161M	163M	163M	160M	161M	159M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TGTX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$18M	($25M)	($41M)	($31M)	($176M)	($296M)	($215M)	($133M)	($129M)	($94M)	($62M)	($45M)	($35M)	($11M)	($5M)	$0M	($2M)	($1M)	($4M)	($10M)	($8M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$18M	($25M)	($41M)	($31M)	($176M)	($296M)	($215M)	($133M)	($129M)	($94M)	($62M)	($45M)	($35M)	($11M)	($5M)	$0M	($2M)	($1M)	($4M)	($10M)	($8M)
FCF Margin %	2.2%	-4.0%	-12.3%	-13.4%	-6326.2%	-4425.7%	-141357.9%	-87458.6%	-84878.3%	-61533.8%	-40645.0%	-29355.7%	-23020.2%	-7107.1%	-27243.6%	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TGTX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$39M	($18M)	$20M	($23M)	$7M	($29M)	($26M)	($12M)	$6M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$39M	($18M)	$20M	($23M)	$7M	($29M)	($26M)	($12M)	$6M
FCF Margin %	16.2%	-8.8%	10.2%	-14.4%	5.2%	-23.8%	-23.7%	-14.6%	7.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TGTX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$1.6B	$1.1B	$578M	$330M	$194M	$380M	$626M	$163M	$84M	$97M	$55M	$113M	$87M	$48M	$22M	$16M	$19M	$0M	$1M	$1M	$3M
Cash & Cash Equivalents	$483M	$79M	$180M	$93M	$102M	$299M	$553M	$113M	$42M	$57M	$25M	$55M	$56M	$40M	$16M	$10M	$0M	$0M	$0M	$1M	$3M
Total Liabilities	$1.0B	$415M	$355M	$169M	$135M	$142M	$106M	$124M	$60M	$97M	$55M	$113M	$87M	$48M	$7M	$6M	$24M	$7M	$6M	$2M	$2M
Total Debt (Short + Long-Term)	$754M	$247M	$246M	$102M	$73M	$69M	$32M	$31M	$0M	$0M	$0M	$0M	$0M	$1M	$3M	$5M	$18M	$2M	$1M	$0M	$0M
Total Shareholders' Equity	$604M	$648M	$222M	$161M	$59M	$237M	$519M	$39M	$24M	$67M	$36M	$102M	$80M	$40M	$16M	$10M	($5M)	($7M)	($4M)	($1M)	$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TGTX viewer.

TGTX Metric Deep Dives

Other Companies in BIOTECHNOLOGY

PTGX · Protagonist Therapeutics Inc — $9 billion
ABVX · Abivax SA American Depositary Shares — $9 billion
CRNX · Crinetics Pharmaceuticals Inc — $9 billion
IBRX · Immunitybio Inc — $9 billion
PCVX · Vaxcyte Inc — $9 billion
CAI · Caris Life Sciences, Inc. Common Stock — $8 billion
PRAX · Praxis Precision Medicines Inc — $8 billion
SYRE · Spyre Therapeutics Inc. — $8 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← TGTA All “T” companies TGVSL →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.